https://feeds.newsfilecorp.com/company/12501 Latest news from Wall Street Wire, as distributed by TMX Newsfile. en CopyRight (c) 2026, Newsfile Corp. All Rights Reserved. office@newsfilecorp.com (Newsfile Corp.) office@newsfilecorp.com (Newsfile Corp.) Tue, 14 Jul 2026 10:43:40 -0400 https://www.newsfilecorp.com/images/newswire/customer-logos/12501.jpg https://feeds.newsfilecorp.com/company/12501 https://www.newsfilecorp.com/release/304934/StreetWatch-Nuvectis-Pharma-Eyes-9.8-Billion-Oral-PNH-Market-With-LateStage-NXP100-Backed-by-Strong-Positive-Phase-3-Data New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharmaceutical Group. Report highlights:Nuvectis Pharma (NASDAQ: NVCT) recently secured worldwide rights outside China to NXP100, a potentially best-in-class once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), along with oncology asset NXP200, from Haisco Pharmaceutical Group. The deal,...<img src="https://api.newsfilecorp.com/newsinfo/304934/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Tue, 14 Jul 2026 10:40:00 -0400 en https://www.newsfilecorp.com/release/304934